Here’s why today and May 19 are important sessions for Zydus Life shareholders – CNBC TV18
Zydus Lifesciences will acquire Assertio Holdings for $23.5 per share in cash, valuing the transaction at $166.4 million. Assertio is a US-based specialty pharmaceutical company with a focus on oncology and pain management.Shares of Zydus Lifesciences Ltd. will remain in focus on Thursday, May 14, amid multiple corporate developments, including a US acquisition and a proposed share buyback. The company…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
